Arbutus Biopharma Corp Stock Issued During Period, Value, Other
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Arbutus Biopharma Corp stock issued during period, value, other for the quarter ending 2017-12-31 was $0.00.
- Arbutus Biopharma Corp stock issued during period, value, other for the quarter ending 2017-09-30 was $0.00.
- Arbutus Biopharma Corp stock issued during period, value, other for the quarter ending 2017-06-30 was $0.00, a 100.00% decline year-over-year.
- Arbutus Biopharma Corp stock issued during period, value, other for the quarter ending 2017-03-31 was $481.00K.
- Arbutus Biopharma Corp stock issued during period, value, other for fiscal 2017 was $481.00K, a 30.49% decline from fiscal 2016.
- Arbutus Biopharma Corp stock issued during period, value, other for fiscal 2016 was $692.00K, a 86.52% increase from fiscal 2015.
- Arbutus Biopharma Corp stock issued during period, value, other for fiscal 2015 was $371.00K, a 96.85% decline from fiscal 2014.
- Arbutus Biopharma Corp stock issued during period, value, other for fiscal 2014 was $11.79M, a 450.21% increase from fiscal 2013.
| Period end | Stock Issued During Period, Value, Other 3 month | Stock Issued During Period, Value, Other 12 month |
|---|---|---|
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | $481.00K 10-K · filed 2019-03-07 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02 | $481.00K derived: sum of 4 quarters · filed 2018-03-16 |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $481.00K derived: sum of 4 quarters · filed 2018-03-16 |
| 2017-03-31 | $481.00K 10-Q · filed 2017-05-04 | $1.17M derived: sum of 4 quarters · filed 2018-03-16 |
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16 | $692.00K 10-K · filed 2018-03-16 |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $686.00K derived: sum of 4 quarters · filed 2018-03-16 |
| 2016-06-30 | $692.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $679.00K derived: sum of 4 quarters · filed 2018-03-16 |
| 2016-03-31 | $0.00 10-Q · filed 2016-05-04 | $96.00K derived: sum of 4 quarters · filed 2018-03-16 |
| 2015-12-31 | -$6.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16 | $371.00K 10-K · filed 2018-03-16 |
| 2015-09-30 | -$7.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | $1.52M derived: sum of 4 quarters · filed 2017-03-22 |
| 2015-06-30 | $109.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-07 | $4.59M derived: sum of 4 quarters · filed 2017-03-22 |
| 2015-03-31 | $275.00K 10-Q · filed 2015-05-06 | $5.22M derived: sum of 4 quarters · filed 2017-03-22 |
| 2014-12-31 | $1.14M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-22 | $11.79M 10-K · filed 2017-03-22 |
| 2014-09-30 | $3.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-07 | |
| 2014-06-30 | $739.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-14 | |
| 2014-03-31 | $6.84M 10-Q · filed 2014-05-14 | |
| 2013-12-31 | $2.14M 10-K · filed 2016-03-09 | |
| 2012-12-31 | 1.51M CAD 20-F · filed 2013-03-27 | |
| 2012-12-31 | $1.51M 10-K · filed 2015-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |